Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 2Sarcoma 1

Conditions

Breast Neoplasms 2Sleep Wake Disorders 1Memory Disorders 1Fatigue 1Depression 1Cognitive Dysfunction 1Cognition Disorders 1Anxiety Disorders 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Donepezil × Breast × Clear all
NCT02822573 2023-09-13

Remember

Wake Forest University Health Sciences

Phase 3 Completed
276 enrolled 33 charts
Breast

Breast Neoplasms, Memory Disorders, Cognitive Dysfunction

NCT01466270 2021-10-20

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Wake Forest University Health Sciences

Phase 2 Completed
62 enrolled 12 charts
Breast

Anxiety Disorders, Breast Neoplasms, Cognition Disorders, Depression, Fatigue, Sleep Wake Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡